eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer

This data was collected in the context of our prospective observational study in patients with advanced non-small cell lung cancer (NSCLC) that aimed to discriminate responders from non-responders after six weeks of immunotherapy treatment by using electronic nose (eNose) analysis of exhaled breath. Between August 2015 and June 2019, 94 patients were included at two thoracic oncology outpatient clinics in The Netherlands (e.g. the Radboudumc, Nijmegen, The Netherlands, and the Netherlands Cancer Institute, Amsterdam, The Netherlands), which were randomized to a training and validation cohort in a 2:1 ratio. In the "Patient characteristics and eNose data" file, clinical and tumor characteristics, and the eNose data of all included patients can be found.